British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...

GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.